Literature DB >> 30959256

Safety Analysis of Two Anterior Lateral Lumbar Interbody Fusions at the Initial Stage of Learning Curve.

Jiaqi Li1, Xianzheng Wang1, Yapeng Sun1, Fei Zhang1, Yuan Gao1, Zeyang Li1, Wenyuan Ding1, Yong Shen1, Wei Zhang2.   

Abstract

OBJECTIVE: Until now, there were few studies on the safety analysis of oblique lumbar interbody fusion (OLIF) and extreme lateral interbody fusion (XLIF) in the initial stage of learning curve. The purpose of this study was to find out the safety differences between the 2 minimally invasive fusion methods in the initial stage of learning curve and to provide reference for beginners.
METHODS: We retrospectively collected the first 30 cases of lumbar degenerative disease with OLIF or XLIF in our center since June 2014. Patients were divided into group OLIF and group XLIF according to different operative methods. The clinical efficacy and complications of the 2 groups were compared. A P <0.05 was statistically significant.
RESULTS: Group XLIF were aged 37-74 years (mean 58.4 years) and group OLIF were aged 39-71 years (mean 56.1 years). There were no significant differences between the 2 groups in age, sex, operation time, intraoperative bleeding volume, operation segment, and follow-up time. The incidence of complications in group XLIF was significantly lower than that in group OLIF (10% vs. 33.3%; P = 0.028).
CONCLUSIONS: OLIF has a higher risk of neurovascular injury in the initial stage of learning. By contrast, the XLIF approach is simple and the incidence of complications is relatively low. Therefore, we believed that XLIF is more acceptable in the initial stage of anterolateral lumbar interbody fusion.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Complication; Extreme lateral interbody fusion; Lumbar degenerative disease; Oblique lumbar interbody fusion

Mesh:

Year:  2019        PMID: 30959256     DOI: 10.1016/j.wneu.2019.03.294

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  7 in total

Review 1.  Incidence of major and minor vascular injuries during lateral access lumbar interbody fusion procedures: a retrospective comparative study and systematic literature review.

Authors:  Alexander O Aguirre; Mohamed A R Soliman; Shady Azmy; Asham Khan; Patrick K Jowdy; Jeffrey P Mullin; John Pollina
Journal:  Neurosurg Rev       Date:  2021-12-01       Impact factor: 3.042

2.  An evaluation of patients with abdominal pain after lateral lumbar interbody fusion.

Authors:  Tristan B Fried; Khoa Tran; Mark J Lambrechts; Nicholas D D'Antonio; Brian A Karamian; Justin Chu; Jose A Canseco; Alan S Hilibrand; Christopher K Kepler; Alexander R Vaccaro; Gregory D Schroeder
Journal:  J Craniovertebr Junction Spine       Date:  2022-09-14

3.  Learning Curve and Complications Experience of Oblique Lateral Interbody Fusion : A Single-Center 143 Consecutive Cases.

Authors:  Bu Kwang Oh; Dong Wuk Son; Su Hun Lee; Jun Seok Lee; Soon Ki Sung; Sang Weon Lee; Geun Sung Song
Journal:  J Korean Neurosurg Soc       Date:  2021-04-30

Review 4.  Perspective on the true incidence of bowel perforations occurring with extreme lateral lumbar interbody fusions. How should they be treated?

Authors:  Nancy E Epstein
Journal:  Surg Neurol Int       Date:  2021-11-23

5.  Extreme Lateral Interbody Fusion for Thoracic and Thoracolumbar Disease: The Diaphragm Dilemma.

Authors:  Alexander Von Glinski; Christopher J Elia; Ariel Takayanagi; Emre Yilmaz; Basem Ishak; Joe Dettori; Benjamin A Schell; Erik Hayman; Clifford Pierre; Jens R Chapman; Rod J Oskouian
Journal:  Global Spine J       Date:  2020-03-27

6.  The OLIF working corridor based on magnetic resonance imaging: a retrospective research.

Authors:  Zhe Wang; Lei Liu; Xiang-He Xu; Ming-de Cao; Hai Lu; Kui-Bo Zhang
Journal:  J Orthop Surg Res       Date:  2020-04-15       Impact factor: 2.359

Review 7.  Review of Risks and Complications of Extreme Lateral Interbody Fusion (XLIF).

Authors:  Nancy E Epstein
Journal:  Surg Neurol Int       Date:  2019-12-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.